Researchers at Seqirus Holly Springs)

EXPERTISE

Leaders in influenza

Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.

Globally we utilise both egg and cell-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies whilst working on longer-term transformational approaches to influenza protection.

As part of the CSL Group, we have been producing egg-based influenza vaccine in Melbourne, Australia since the 1940’s. Our site in Liverpool UK, is a Centre of Excellence for adjuvanted influenza vaccine manufacturing while our state-of-the-art production facility in Holly Springs US, was purpose-built to harness newer cell-based technology.

Little boy with bandaid

About Influenza

Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people.

Learn more
  • 3 to 5 million

    Cases of severe illness resulting from annual flu epidemics.1

  • up to 650,000

    potential respiratory deaths linked to seasonal flu each year.1

  • US$27 billion

    Annual medical care and lost labour costs in the US alone.2

Areas of expertise

Influenza

Influenza

We are one of the world’s largest influenza vaccine companies with a singular global focus on influenza.

GISAID

Pandemic Response Solutions

Experts agree that there will be another influenza pandemic this century3. Seqirus offers a portfolio of pandemic vaccines and services for rapid response.

Consumer Pain Campaign AU 1

In-Licensing

Seqirus is the largest fully integrated commercialisation partner for vaccines and pharmaceuticals in Australia and New Zealand.

AVAT / Q Vax - red bellied black snake

Antivenoms & Q fever Vaccine

Seqirus is the supplier of a unique range of antivenoms and Q fever vaccine for the Australian government.

1 World Health Organisation. Influenza (seasonal) Fact Sheet, November 2018. Available online: http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) (Accessed March 2019)
2 de Boer, P. et al, A systematic review of health economic consequences of quadrivalent influenza vaccination, Expert review of Pharmacoeconomics & Outcomes Research, Volume 17, 2017 - Issue 3, p249-265. https://doi.org/10.1080/14737167.2017.1343145
World Health Organisation. Newsroom Feature. 8 Things to know about pandemic influenza. Available online: https://www.who.int/news-room/feature-stories/detail/8-things-to-know-about-pandemic-influenza (Accessed June 2019)

 

SEQ/CORP/0819/0021